Within the context of PD-L1 downregulation on tumor cells mediated by miR-495, the group receiving the combined treatment exhibited enhanced proliferation of splenic lymphocytes, an increased proportion of macrophages in the splenic suspension, and augmented T cell activation. This evidence concerns the gene CD274 and neoplasm.